Poseida shares plunge after death in solid tumor CAR-T trial, clinical hold

Poseida Therapeutics saw its shares plummet after-hours Monday when it revealed in a Securities and Exchange Commission (SEC) filing that its cancer drug has been slapped with a full clinical hold.

The hold has hit its phase 1 test for P-PSMA-101 in metastatic castration-resistant prostate cancer and comes after a patient died of liver failure in the study, the cause of which could “possibly related to P-PSMA-101 pending further investigation,” the biotech said in the SEC filing.